Literature DB >> 27172833

Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis.

Abdulrahman Alsultan1, Andrew J Gale2, Kadijah Kurban3, Mohammed Khalifah3, Fahad B Albadr4, John H Griffin2.   

Abstract

INTRODUCTION: We describe a family with two first-degree cousins who presented with similar phenotypes characterized by neonatal intracranial hemorrhage and subsequent onset of thrombosis. PATIENTS/
METHODS: We enrolled the two affected patients, five unaffected family members and fifty-five normal controls. Clinical, laboratory, and radiological characteristics of patients were obtained. Exome sequencing was performed for the older affected child. PROC c.811 C>T was genotyped by PCR in patients, family members, and controls. Protein C amidolytic activity and antigen were measured using the STACHROM® protein C kit and ELISAs. To define functional abnormalities caused by the patients' mutation, recombinant wildtype protein C and its mutants R229W, R229Q and R229A were studied.
RESULTS: For the two cousins, protein C amidolytic activity was 61% and 59% and antigen was 57% and 73% (nl 70-140%), respectively. Exome sequencing revealed a homozygous variant in exon 9 of the protein C (PROC) gene c.811 C>T (R229W). The R229W mutation is located in the calcium binding loop of protein C's protease domain that mediates thrombomodulin interactions. Recombinant R229W-protein C mutant was strikingly defective in rate of activation by thrombin: thrombomodulin, suggesting an in vivo deficit in these children for generation of activated protein C.
CONCLUSIONS: These cases emphasize that protein C and activated protein C are important in maintaining the integrity of the brain vascular endothelium in humans. Moreover, routine protein C assays utilizing snake venom protease fail to detect protein C mutants that are resistant to thrombin:thrombomodulin activation.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Intracranial hemorrhage; Mutation; Neonate; Protein C; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27172833      PMCID: PMC4943460          DOI: 10.1016/j.thromres.2016.04.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  20 in total

1.  Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C.

Authors:  Andrew J Gale; Alexander Tsavaler; John H Griffin
Journal:  J Biol Chem       Date:  2002-06-12       Impact factor: 5.157

Review 2.  The cytoprotective protein C pathway.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  p-Nitrophenyl-p'-guanidinobenzoate HCl: a new active site titrant for trypsin.

Authors:  T Chase; E Shaw
Journal:  Biochem Biophys Res Commun       Date:  1967-11-30       Impact factor: 3.575

Review 4.  Cytoprotective protein C pathways and implications for stroke and neurological disorders.

Authors:  Berislav V Zlokovic; John H Griffin
Journal:  Trends Neurosci       Date:  2011-02-25       Impact factor: 13.837

Review 5.  Activated protein C: biased for translation.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

Review 6.  Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

Review 7.  Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH.

Authors:  P H Reitsma; F Bernardi; R G Doig; S Gandrille; J S Greengard; H Ireland; M Krawczak; B Lind; G L Long; S R Poort
Journal:  Thromb Haemost       Date:  1995-05       Impact factor: 5.249

8.  Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.

Authors:  M J Heeb; R Bischoff; M Courtney; J H Griffin
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

9.  Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va.

Authors:  Andrew J Gale; John H Griffin
Journal:  Proteins       Date:  2004-02-15

Review 10.  Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis.

Authors:  R A Marlar; R R Montgomery; A W Broekmans
Journal:  J Pediatr       Date:  1989-04       Impact factor: 4.406

View more
  1 in total

1.  Rational Design of Protein C Activators.

Authors:  Sergio Barranco-Medina; Mary Murphy; Leslie Pelc; Zhiwei Chen; Enrico Di Cera; Nicola Pozzi
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.